Close Menu

NEW YORK – Rare disease diagnostics and research firm Centogene said on Thursday that it plans to sell a total of 3.5 million common shares in a primary and secondary public stock offering.

The offering consists of 2 million common shares offered by the company and 1.5 million common shares offered by selling shareholders at a price of $14 per share, for gross proceeds of $28 million and $21 million, respectively. Centogene will not receive any proceeds from the sale by the selling shareholders.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.